#biosimilar — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #biosimilar, aggregated by home.social.
-
Samsung Bioepis launches SB17, a biosimilar of Johnson & Johnson's Stelara for autoimmune diseases, in Japan through partner Nipro Corporation, marking its first biosimilar entry into the Japanese market while already selling the product as Pyzchiva in Europe and the US, and Epiztek in South Korea.
#YonhapInfomax #SamsungBioepis #Biosimilar #SB17 #JapanMarket #AutoimmuneDisease #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=121456 -
Samsung Bioepis launches SB17, a biosimilar of Johnson & Johnson's Stelara for autoimmune diseases, in Japan through partner Nipro Corporation, marking its first biosimilar entry into the Japanese market while already selling the product as Pyzchiva in Europe and the US, and Epiztek in South Korea.
#YonhapInfomax #SamsungBioepis #Biosimilar #SB17 #JapanMarket #AutoimmuneDisease #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=121456 -
Samsung Bioepis launches SB17, a biosimilar of Johnson & Johnson's Stelara for autoimmune diseases, in Japan through partner Nipro Corporation, marking its first biosimilar entry into the Japanese market while already selling the product as Pyzchiva in Europe and the US, and Epiztek in South Korea.
#YonhapInfomax #SamsungBioepis #Biosimilar #SB17 #JapanMarket #AutoimmuneDisease #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=121456 -
Samsung Bioepis launches SB17, a biosimilar of Johnson & Johnson's Stelara for autoimmune diseases, in Japan through partner Nipro Corporation, marking its first biosimilar entry into the Japanese market while already selling the product as Pyzchiva in Europe and the US, and Epiztek in South Korea.
#YonhapInfomax #SamsungBioepis #Biosimilar #SB17 #JapanMarket #AutoimmuneDisease #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=121456 -
Samsung Bioepis launches SB17, a biosimilar of Johnson & Johnson's Stelara for autoimmune diseases, in Japan through partner Nipro Corporation, marking its first biosimilar entry into the Japanese market while already selling the product as Pyzchiva in Europe and the US, and Epiztek in South Korea.
#YonhapInfomax #SamsungBioepis #Biosimilar #SB17 #JapanMarket #AutoimmuneDisease #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=121456 -
🌍 Pharma IPR is now a strategic business function.
Learn US EU & Global Pharma Patent Strategy, Biosimilar Patent Dance, Para IV, FTO Analysis, Licensing Portfolio Management through hands-on training -
Organon gets EU approval for POHERDY biosimilar
Key Terms
biosimilar
medical
A biosimilar is a…
#Europe #EU #biosimilar #breastcancer #EuropeanCommissionapproval #EuropeanUnion #Henlius #OGN #Organon #pertuzumab #POHERDY
https://www.europesays.com/europe/26010/ -
Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.
#YonhapInfomax #Celltrion #Truxima #US Market Share #Rituximab #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114173 -
Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.
#YonhapInfomax #Celltrion #Truxima #US Market Share #Rituximab #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114173 -
Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.
#YonhapInfomax #Celltrion #Truxima #US Market Share #Rituximab #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114173 -
Celltrion's biosimilar Truxima captures 35.8% US prescription market share as of February 2026, becoming the top rituximab drug six years after market entry, with North American sales exceeding 300 billion won and 40% year-over-year growth demonstrating strong competitive positioning in the world's largest pharmaceutical market.
#YonhapInfomax #Celltrion #Truxima #US Market Share #Rituximab #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=114173 -
South Korea’s Biosimilar Boom Enters High-Stakes ‘Third Wave’
South Korea’s Biosimilar Boom Enters High-Stakes ‘Third Wave’ April 1, 2026 | Wednesday | Analysis | By Ayesha…
#Conflict #Conflicts #War #biosimilar #investment #korea #northkorea #research
https://www.europesays.com/2886640/ -
Samsung Bioepis posts sharp 60% year-on-year drop in Q4 operating profit, signaling challenges for South Korea's biosimilar sector.
#YonhapInfomax #SamsungBioepis #OperatingProfit #Q4Earnings #Biosimilar #YearOnYearDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102024 -
Samsung Bioepis posts sharp 60% year-on-year drop in Q4 operating profit, signaling challenges for South Korea's biosimilar sector.
#YonhapInfomax #SamsungBioepis #OperatingProfit #Q4Earnings #Biosimilar #YearOnYearDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102024 -
Samsung Bioepis posts sharp 60% year-on-year drop in Q4 operating profit, signaling challenges for South Korea's biosimilar sector.
#YonhapInfomax #SamsungBioepis #OperatingProfit #Q4Earnings #Biosimilar #YearOnYearDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102024 -
Samsung Bioepis posts sharp 60% year-on-year drop in Q4 operating profit, signaling challenges for South Korea's biosimilar sector.
#YonhapInfomax #SamsungBioepis #OperatingProfit #Q4Earnings #Biosimilar #YearOnYearDrop #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102024 -
Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100079 -
Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100079 -
Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100079 -
Samsung Bioepis Holdings announced plans to expand into new drug development, leveraging its biosimilar success, with a goal of 20 products by 2030 and annual clinical-stage candidates, as outlined by CEO Kim Kyung-ah at the JP Morgan Healthcare Conference.
#YonhapInfomax #SamsungBioepisHoldings #Biosimilar #NewDrugDevelopment #JPmorganHealthcareConference #KimKyungAh #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=100079 -
Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705 -
Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705 -
Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705 -
Celltrion has launched its biosimilar ophthalmic drug Eydenzelt in major European markets, securing NHS tenders in the UK and expanding its presence across Europe to accelerate prescriptions, targeting a share of the $9.5 billion global market for Eylea.
#YonhapInfomax #Celltrion #Eydenzelt #Biosimilar #EuropeanMarket #EyleaSales #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=95705 -
🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới
🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu Trong vòng một thập niên, Keytruda (Pembrolizumab) của Merck đã tạo nên kỷ lục hiếm có: doanh thu vượt 146 tỷ USD, trở thành thuốc ung thư bán chạy nhất thế giới.
-
🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nh ất thế giới
🌿 Toàn cảnh Keytruda – Thuốc ung thư bán chạy nhất thế giới 💖👉🍀🍀🤔 #ungthu #Keytruda #miendich #Merck #biosimilar #suckhoe 1️⃣ Vị thế số một của Keytruda trên thị trường toàn cầu Trong vòng một thập niên, Keytruda (Pembrolizumab) của Merck đã tạo nên kỷ lục hiếm có: doanh thu vượt 146 tỷ USD, trở thành thuốc ung thư bán chạy nhất thế giới.
-
Celltrion has received additional FDA approval for its Yuflyma 10mg pre-filled syringe, expanding its US high-concentration biosimilar lineup for pediatric autoimmune treatment.
#YonhapInfomax #Celltrion #Yuflyma #FDAApproval #Biosimilar #JuvenileIdiopathicArthritis #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88896 -
Celltrion has received additional FDA approval for its Yuflyma 10mg pre-filled syringe, expanding its US high-concentration biosimilar lineup for pediatric autoimmune treatment.
#YonhapInfomax #Celltrion #Yuflyma #FDAApproval #Biosimilar #JuvenileIdiopathicArthritis #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88896 -
Celltrion has received additional FDA approval for its Yuflyma 10mg pre-filled syringe, expanding its US high-concentration biosimilar lineup for pediatric autoimmune treatment.
#YonhapInfomax #Celltrion #Yuflyma #FDAApproval #Biosimilar #JuvenileIdiopathicArthritis #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88896 -
Celltrion has received additional FDA approval for its Yuflyma 10mg pre-filled syringe, expanding its US high-concentration biosimilar lineup for pediatric autoimmune treatment.
#YonhapInfomax #Celltrion #Yuflyma #FDAApproval #Biosimilar #JuvenileIdiopathicArthritis #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88896 -
Celltrion has received regulatory approval in New Zealand for Stekeyma, its biosimilar to Stelara, expanding access to autoimmune disease treatments in a $21.66 billion global market.
#YonhapInfomax #Celltrion #Stekeyma #Biosimilar #Ustekinumab #NewZealandApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=85542 -
Celltrion has received regulatory approval in New Zealand for Stekeyma, its biosimilar to Stelara, expanding access to autoimmune disease treatments in a $21.66 billion global market.
#YonhapInfomax #Celltrion #Stekeyma #Biosimilar #Ustekinumab #NewZealandApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=85542 -
Celltrion has received regulatory approval in New Zealand for Stekeyma, its biosimilar to Stelara, expanding access to autoimmune disease treatments in a $21.66 billion global market.
#YonhapInfomax #Celltrion #Stekeyma #Biosimilar #Ustekinumab #NewZealandApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=85542 -
Celltrion has received regulatory approval in New Zealand for Stekeyma, its biosimilar to Stelara, expanding access to autoimmune disease treatments in a $21.66 billion global market.
#YonhapInfomax #Celltrion #Stekeyma #Biosimilar #Ustekinumab #NewZealandApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=85542 -
Celltrion has secured US FDA approval for its Eylea biosimilar, Eydenzelt, expanding its US portfolio, though commercial launch is delayed amid ongoing patent litigation with Regeneron.
#YonhapInfomax #Celltrion #FDAApproval #Eydenzelt #Biosimilar #PatentDispute #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=84948 -
Celltrion has secured US FDA approval for its Eylea biosimilar, Eydenzelt, expanding its US portfolio, though commercial launch is delayed amid ongoing patent litigation with Regeneron.
#YonhapInfomax #Celltrion #FDAApproval #Eydenzelt #Biosimilar #PatentDispute #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=84948 -
Celltrion has secured US FDA approval for its Eylea biosimilar, Eydenzelt, expanding its US portfolio, though commercial launch is delayed amid ongoing patent litigation with Regeneron.
#YonhapInfomax #Celltrion #FDAApproval #Eydenzelt #Biosimilar #PatentDispute #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=84948 -
Celltrion has secured US FDA approval for its Eylea biosimilar, Eydenzelt, expanding its US portfolio, though commercial launch is delayed amid ongoing patent litigation with Regeneron.
#YonhapInfomax #Celltrion #FDAApproval #Eydenzelt #Biosimilar #PatentDispute #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=84948 -
Celltrion has obtained Japanese regulatory approval for its Actemra biosimilar Avtozma, targeting key autoimmune indications and aiming to expand its presence in Japan’s pharmaceutical market.
#YonhapInfomax #Celltrion #Avtozma #Biosimilar #JapanApproval #AutoimmuneDiseases #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82759 -
Celltrion has obtained Japanese regulatory approval for its Actemra biosimilar Avtozma, targeting key autoimmune indications and aiming to expand its presence in Japan’s pharmaceutical market.
#YonhapInfomax #Celltrion #Avtozma #Biosimilar #JapanApproval #AutoimmuneDiseases #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82759 -
Celltrion has obtained Japanese regulatory approval for its Actemra biosimilar Avtozma, targeting key autoimmune indications and aiming to expand its presence in Japan’s pharmaceutical market.
#YonhapInfomax #Celltrion #Avtozma #Biosimilar #JapanApproval #AutoimmuneDiseases #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82759 -
Celltrion has obtained Japanese regulatory approval for its Actemra biosimilar Avtozma, targeting key autoimmune indications and aiming to expand its presence in Japan’s pharmaceutical market.
#YonhapInfomax #Celltrion #Avtozma #Biosimilar #JapanApproval #AutoimmuneDiseases #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82759 -
Celltrion Co. has announced its ninth share buyback of 2025, approving an additional 100 billion won repurchase as part of ongoing efforts to boost shareholder value and signal confidence in future growth.
#YonhapInfomax #Celltrion #ShareBuyback #Biosimilar #TreasuryShares #ShareholderValue #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82074 -
Celltrion Co. has announced its ninth share buyback of 2025, approving an additional 100 billion won repurchase as part of ongoing efforts to boost shareholder value and signal confidence in future growth.
#YonhapInfomax #Celltrion #ShareBuyback #Biosimilar #TreasuryShares #ShareholderValue #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82074 -
Celltrion Co. has announced its ninth share buyback of 2025, approving an additional 100 billion won repurchase as part of ongoing efforts to boost shareholder value and signal confidence in future growth.
#YonhapInfomax #Celltrion #ShareBuyback #Biosimilar #TreasuryShares #ShareholderValue #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82074 -
Celltrion Co. has announced its ninth share buyback of 2025, approving an additional 100 billion won repurchase as part of ongoing efforts to boost shareholder value and signal confidence in future growth.
#YonhapInfomax #Celltrion #ShareBuyback #Biosimilar #TreasuryShares #ShareholderValue #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=82074 -
Biocon Biologics Receives Health Canada Approval for https://www.byteseu.com/1142018/ #Aflibercept #BioconBiologicsLtd #biosimilar #Canada #HealthCanada #NationalStockExchangeOfIndiaLimited:BIOCON.NS #ophthalmology
-
Celltrion Co. advanced its global expansion strategy at BIO USA 2025 in Boston, holding over 150 meetings to strengthen partnerships and pipeline, as it targets growth into a global big pharma.
#YonhapInfomax #Celltrion #BIOUSA #GlobalPartnerships #Biosimilar #AntibodyDrugConjugate #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=68476 -
Celltrion Co. advanced its global expansion strategy at BIO USA 2025 in Boston, holding over 150 meetings to strengthen partnerships and pipeline, as it targets growth into a global big pharma.
#YonhapInfomax #Celltrion #BIOUSA #GlobalPartnerships #Biosimilar #AntibodyDrugConjugate #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=68476 -
Celltrion Co. advanced its global expansion strategy at BIO USA 2025 in Boston, holding over 150 meetings to strengthen partnerships and pipeline, as it targets growth into a global big pharma.
#YonhapInfomax #Celltrion #BIOUSA #GlobalPartnerships #Biosimilar #AntibodyDrugConjugate #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=68476